July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Stephen V Liu: Alexander Drilon at CIOT25 Clearly Favoring Taletrectinib as 1L for ROS1 NSCLC
Jun 20, 2025, 09:34

Stephen V Liu: Alexander Drilon at CIOT25 Clearly Favoring Taletrectinib as 1L for ROS1 NSCLC

Stephen V Liu, Director of Thoracic Oncology and Associate Professor of Medicine at Georgetown University, shared a post on X:

“Dr. Alexander Drilon at CIOT25 clearly favoring taletrectinib as 1L for ROS1 NSCLC – potential and better tox profile. NVL-520 zidesamtinib poised to potentially be best in class. For RET, after selpercatinib or pralsetinib, few options. EP0031 is one in development.”

CIOT25

More posts featuring Stephen V Liu.